<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anticoagulant rodenticide poisoning: Management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anticoagulant rodenticide poisoning: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Anticoagulant rodenticide poisoning: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane P Calello, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Erica L Liebelt, MD, FACMT</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1293484743"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This topic reviews the management of anticoagulant rodenticide (also called long-acting anticoagulant rodenticide; LAAR) poisoning.</p><p>The clinical manifestations and diagnosis of anticoagulant rodenticide poisoning and an overview of rodenticide poisonings other than anticoagulant rodenticides is provided separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/100310.html" rel="external">"Anticoagulant rodenticide poisoning: Clinical manifestations and diagnostic evaluation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/94398.html" rel="external">"Overview of rodenticide poisoning"</a>.)</p><p></p><p class="headingAnchor" id="H608858047"><span class="h1">INDICATIONS FOR MEDICAL EVALUATION</span><span class="headingEndMark"> — </span>Not all ingestions of anticoagulant rodenticides warrant medical evaluation. The need for medical evaluation is determined by the clinical circumstances and the potential toxicity of the reported exposure. We consider a nontoxic dose to be &lt;1 mg. However, with most anticoagulant rodenticide ingestions, the exact amount is difficult to determine and the clinical circumstances and type of formulation ingested is used to determine if an exposure is potentially toxic. We encourage determination of toxicity and need for evaluation in consultation with a regional poison control center, whenever possible. (See <a class="local">'Regional poison control centers'</a> below.)</p><p>Our approach to patients after exposure to long-acting or <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> anticoagulant rodenticides are based upon the guideline published by the American Association of Poison Control Centers as follows [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Emergency department evaluation</strong> – Immediate referral to an emergency department, regardless of estimated dose ingested or exposure, is warranted for all of the following patients:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Signs of bleeding or bruising (symptomatic patients)</p><p class="bulletIndent2"><span class="glyph">•</span>Intentional exposure (eg, self-harm, misuse, abuse, or malicious intent)</p><p class="bulletIndent2"><span class="glyph">•</span>High dose exposures</p><p></p><p class="bulletIndent1">Referral of patients with unintentional toxic ingestions (estimated dose &gt;1 mg) or ingestions of an unknown amount for administration of activated charcoal is also appropriate if treatment can be accomplished within one hour of exposure.</p><p></p><p class="bulletIndent1">Recommendations for further care of these patients based upon clinical findings is discussed below. (See <a class="local">'Management'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outpatient evaluation</strong> – Outpatient evaluation and laboratory testing at a facility that is capable of obtaining and providing results within 24 hours for post-exposure monitoring is appropriate for the following asymptomatic patients (see  <a class="medical medical_review" href="/z/d/html/100310.html" rel="external">"Anticoagulant rodenticide poisoning: Clinical manifestations and diagnostic evaluation", section on 'Ancillary studies'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unintentional ingestion of or exposure to long-acting rodenticides by patients on anticoagulant therapy (baseline prothrombin time [PT], international normalized ratio [INR], and partial thromboplastin time (aPTT) as soon as possible after ingestion with repeat measurements 48 to 72 hours after exposure)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ingestion in a pregnant patient (evaluation by obstetrician or primary care provider on the day of ingestion with measurement of PT/INR at 48 to 72 hours)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unintentional potentially toxic dose in patients without bleeding or bruising (evaluation and measurement of PT/INR 48 to 72 hours after exposure)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Observation at home</strong> – Children and older patients with nontoxic ingestions (eg, one handful or less of low concentration cereal baits) do not need evaluation or blood testing and can undergo observation at home. The patient or caregivers should be advised to watch for signs of bleeding (eg, bruising, epistaxis, oral bleeding, hematuria, or hematochezia) and to seek medical attention if they occur. Based upon observational studies, these patients rarely develop coagulopathy or bleeding [<a href="#rid2">2-6</a>]. Furthermore, no serious hemorrhage has been described in such patients.</p><p></p><p class="headingAnchor" id="H1911419671"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The management of anticoagulant rodenticide exposure depends upon clinical findings and estimated dose. Consultation with a regional poison control center is encouraged for all exposures. (See <a class="local">'Regional poison control centers'</a> below.)</p><p>Not all patients who ingest an anticoagulant rodenticide warrant medical evaluation. (See <a class="local">'Indications for medical evaluation'</a> above.)</p><p class="headingAnchor" id="H2361079543"><span class="h2">Nontoxic exposures</span><span class="headingEndMark"> — </span>Otherwise healthy patients with nontoxic ingestions of anticoagulant rodenticides such as exploratory ingestions in children do not require medical evaluation or laboratory testing. (See <a class="local">'Indications for medical evaluation'</a> above.)</p><p>Pregnant women and patients on anticoagulant therapy warrant further evaluation as discussed separately. (See <a class="local">'Indications for medical evaluation'</a> above and  <a class="medical medical_review" href="/z/d/html/100310.html" rel="external">"Anticoagulant rodenticide poisoning: Clinical manifestations and diagnostic evaluation", section on 'Acute or chronic exposure'</a>.)</p><p class="headingAnchor" id="H2623333571"><span class="h2">Toxic exposures</span><span class="headingEndMark"> — </span>Toxic exposures warrant timely evaluation for gastrointestinal decontamination and are subsequently managed based upon whether coagulopathy or bleeding are present.</p><p class="headingAnchor" id="H1066929511"><span class="h3">Gastrointestinal decontamination</span><span class="headingEndMark"> — </span>We recommend that patients who have ingested toxic amounts of anticoagulant rodenticides receive activated charcoal (AC) orally as long as the following conditions are met:</p><p class="bulletIndent1"><span class="glyph">●</span>Normal mental status and no aspiration risk</p><p class="bulletIndent1"><span class="glyph">●</span>Ingestion of an estimated dose that is &gt;1 mg of anticoagulant rodenticide</p><p class="bulletIndent1"><span class="glyph">●</span>AC can be administered within one hour of ingestion</p><p></p><p>For patients who present more than one hour after ingestion the use of activated charcoal should be individualized based upon the amount of rodenticide ingested, the potential for adverse effects of AC, and presence of other factors (eg, coingestants) that may slow gastric emptying. AC is unlikely to be of significant benefit more than <strong>two</strong> hours after ingestion, but may be warranted later in large ingestions where even marginally diminished dose may confer benefit. This recommendation for AC is based upon indirect evidence that AC slows absorption of ingested toxins and that AC binds compounds like <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> and superwarfarins. (See  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Evidence of efficacy and adverse effects'</a>.)</p><p>Evidence is lacking to support the use of whole bowel irrigation (WBI) with polyethylene glycol electrolyte solution (1 to 2 L/hr via naso- or oro-gastric tube) following anticoagulant rodenticide poisoning, and these products do not exhibit sustained-release toxicokinetics. However, it may be an option for very large ingestions or ingestions of intact packets of bait cereal. (See  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Whole bowel irrigation'</a>.)</p><p>Gastric lavage has no role in the management of anticoagulant rodenticide poisoning and is of limited usefulness following poisoning in general. (See  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Gastric lavage'</a>.)</p><p class="headingAnchor" id="H1066147217"><span class="h3">No coagulopathy</span><span class="headingEndMark"> — </span>Patients with normal coagulation testing at 48 hours are <strong>not</strong> at risk of developing coagulopathy or bleeding. Further care should focus on poisoning prevention in patients with unintentional exposures and identification and treatment of psychiatric disease in patients intending self-harm. (See <a class="local">'Intentional exposures'</a> below.)</p><p class="headingAnchor" id="H2220163831"><span class="h3">Coagulopathy but no bleeding</span><span class="headingEndMark"> — </span>The management of coagulopathy but no bleeding varies by type of rodenticide as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Superwarfarin poisoning</strong> – In the otherwise healthy patient with no bleeding, treatment should center on the measurement of prothrombin time (PT) and international normalized ratio (INR). An INR of &lt;4.5 in a patient with no bleeding warrants only observation and serial monitoring. Based upon experience with this degree of anticoagulation in patients on <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> anticoagulant therapy, the risk of spontaneous bleeding is low for these patients. However, they should be told to modify activities to avoid the risk of falls or head trauma until they have normal coagulation. (See  <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'INR &lt;4.5 without bleeding'</a>.)</p><p></p><p class="bulletIndent1">In otherwise healthy patients with an INR ≥4.5 and no bleeding, we suggest treatment with oral vitamin K<sub>1</sub> rather than intravenous vitamin K<sub>1</sub> to avoid the risk of anaphylaxis associated with intravenous administration. There is little agreement as to dosing. A starting oral dose of 10 mg per day with ongoing monitoring of coagulation status is a reasonable approach. Pediatric dosing should begin at 1 to 2.5 mg orally, however more may be needed depending on the dose of anticoagulant ingested. We measure the INR every 48 to 72 hours and progressively increase the oral dose until the INR &lt;1.5. In case reports, required daily doses of vitamin K<sub>1</sub> range from 15 to 600 mg for 30 to 200 days, with widely varied endpoints [<a href="#rid7">7-12</a>]. These patients also warrant modification of activities to avoid trauma. (See  <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'INR 4.5 to 10 without bleeding'</a>.)</p><p></p><p class="bulletIndent1">There is little agreement as to duration and approach to cessation of vitamin K<sub>1</sub> therapy. We advise consultation with and referral to a hematologist for long-term management. Either tapering the dose or cessation of vitamin K<sub>1</sub> followed by measurement of coagulation parameters 48 to 72 hours following the dosing change are reasonable approaches [<a href="#rid13">13</a>]. Coagulation parameters must be measured for several weeks after cessation to ensure no relapse of coagulopathy or bleeding [<a href="#rid7">7</a>]. This approach is based upon experience with supratherapeutic INR of ≥4.5 in patients receiving <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> who are at higher risk of bleeding. Some experts advocate for weekly measurement of quantitative superwarfarin (ie, LAAR) concentrations and continue vitamin K<sub>1</sub> until &lt;10 ng/mL [<a href="#rid7">7,9,14</a>]. Use of these assays provide a clear end-point to therapy and obviates the need to monitor coagulation parameters following cessation of vitamin K<sub>1</sub>, but they are not widely available [<a href="#rid15">15</a>]. </p><p></p><p class="bulletIndent1">Patients on anticoagulant therapy should have cessation or adjustment of their regimen and receive oral vitamin K<sub>1</sub> based upon their INR in consultation with the prescribing physician and a hematologist.</p><p></p><p class="bulletIndent1">Vitamin K<sub>1</sub> tablet formulations are very expensive, and supplies can quickly be depleted in a mass poisoning outbreak. Oral administration of injectable vitamin K<sub>1</sub> preparations has been previously used effectively and safely under these circumstances [<a href="#rid16">16,17</a>]. If oral vitamin K<sub>1</sub> is unavailable in sufficient quantities, we suggest consultation with a clinical pharmacist and poison control center. (See <a class="local">'Regional poison control centers'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">Warfarin</a><strong> poisoning</strong> – After ingestion of a warfarin rodenticide, patients who are <strong>not</strong> on warfarin chronically and who have an INR &gt;10 should receive 2.5 to 5 mg vitamin K<sub>1</sub> orally with reassessment of the INR in 24 hours to determine need for an additional dose. Patients with an INR ≤10 are at lower risk of bleeding and in most instances, avoidance of further warfarin exposure is sufficient. However, vitamin K<sub>1</sub> 1 to 2.5 mg is an option for patients who are at increased risk of bleeding  (<a class="graphic graphic_table graphicRef119954" href="/z/d/graphic/119954.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Treatment of supratherapeutic INR without bleeding'</a>.)</p><p></p><p class="bulletIndent1">Patients on <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> therapy who ingest warfarin-containing rodenticides should have their regimen managed and oral vitamin K<sub>1</sub> administered with input from their prescribing physician and a hematologist according to the degree of INR elevation. </p><p></p><p class="headingAnchor" id="H4061723013"><span class="h3">Coagulopathy and active bleeding</span><span class="headingEndMark"> — </span>Consultation with a hematologist and medical toxicologist is advised for any patient with bleeding after ingestion of an anticoagulant rodenticide. These patients warrant modification of activities to avoid the risk of falls or head trauma until their coagulopathy is controlled.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minor bleeding</strong> - Patients with minor bleeding (eg, limited epistaxis or ecchymosis) should receive vitamin K<sub>1</sub> orally. Dosing is much higher and must continue for a longer period of time after superwarfarin ingestion than when vitamin K<sub>1 </sub>is given for reversal of excess <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>. (See  <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Minimal bleeding'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Major bleeding</strong> – We recommend that patients with life-threatening bleeding (eg, intracranial, genitourinary, or gastrointestinal hemorrhage) following anticoagulant rodenticide poisoning emergently receive <a class="drug drug_general" data-topicid="9450" href="/z/d/drug information/9450.html" rel="external">4-factor prothrombin complex concentrate</a> (PCC), if available, or 3-factor PCC and <strong>either</strong> recombinant factor VIIa <strong>or</strong> fresh frozen plasma (FFP). If neither 3-factor nor 4-factor PCC is available, then FFP should be given by rapid infusion [<a href="#rid2">2,18,19</a>]. Intravenous vitamin K<sub>1</sub> should also be given but does <strong>not</strong> have an immediate effect on restoring normal coagulation. This recommendation is derived from limited observational evidence in patients with major bleeding after anticoagulant rodenticide poisoning or <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> overdose. Patients with major bleeding should be on bed rest.</p><p></p><p class="bulletIndent1">The following table summarizes the initial emergency treatment of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> anticoagulation for life-threatening hemorrhage in adults and provides a suggested approach that is also applicable to anticoagulant rodenticide poisoning  (<a class="graphic graphic_table graphicRef89478" href="/z/d/graphic/89478.html" rel="external">table 2</a>). This approach and the supporting evidence are further discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Serious/life-threatening bleeding'</a>.)</p><p></p><p class="bulletIndent1">Dosing of reversal agents for pediatric patients is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PCC (3- or 4-factor)</strong> – 25 to 50 international units/kg (maximum dose 2000 international units)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>FFP</strong> – 15 to 30 mL/kg (maximum single dose 2 units)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Factor VIIa</strong> – 20 mcg/kg without maximum dose (as for congenital factor VII deficiency)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vitamin K</strong><strong><sub>1 </sub></strong>– 0.3 mg/kg intravenously (maximum single dose 10 mg)</p><p></p><p class="headingAnchor" id="H3280126839"><span class="h3">Elimination enhancement</span><span class="headingEndMark"> — </span>After absorption of anticoagulant rodenticides has occurred, there are limited efficacy data for enhanced elimination of these compounds. Thus, techniques such as multiple dose activated charcoal, hemodialysis, or <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a> are not typically used [<a href="#rid2">2,20-22</a>]. Of these, only cholestyramine has been shown to enhance elimination of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> or superwarfarin compounds from the gastrointestinal tract based upon small pharmacokinetic studies in healthy adults and one case report that used duration of coagulopathy as an endpoint [<a href="#rid21">21,22</a>].</p><p class="headingAnchor" id="H3731247141"><span class="h2">Intentional exposures</span><span class="headingEndMark"> — </span>Patients who ingest anticoagulant rodenticides to harm themselves warrant psychiatric consultation once they are medically stable and prior to hospital discharge. (See  <a class="medical medical_review" href="/z/d/html/1708.html" rel="external">"Suicidal ideation and behavior in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1230.html" rel="external">"Suicidal ideation and behavior in children and adolescents: Evaluation and management"</a>.)</p><p>Children who have been intentionally given anticoagulant rodenticides have suffered physical abuse. They warrant evaluation by a child abuse specialist and team and should be reported to child protection agencies. (See  <a class="medical medical_review" href="/z/d/html/6608.html" rel="external">"Medical child abuse (Munchausen syndrome by proxy)", section on 'Management'</a>.)</p><p>Adults who ingest anticoagulant rodenticides to feign a medical illness require psychiatric referral. (See  <a class="medical medical_review" href="/z/d/html/7765.html" rel="external">"Factitious disorder imposed on self (Munchausen syndrome)"</a>.)</p><p class="headingAnchor" id="H3184458772"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H948902739"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p>In addition, some hospitals have clinical and/or medical toxicologists available for bedside consultation and/or inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of toxic exposures.</p><p class="headingAnchor" id="H394320145"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114014.html" rel="external">"Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114614.html" rel="external">"Society guideline links: Anticoagulation"</a>.)</p><p class="headingAnchor" id="H1370036224"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for medical evaluation</strong> – The need for medical evaluation after anticoagulant rodenticide ingestion is determined by the clinical circumstances and the potential toxicity of the reported exposure. We consider a nontoxic dose to be &lt;1 mg. However, with most anticoagulant rodenticide ingestions, the exact amount is difficult to determine and the clinical circumstances and type of formulation ingested is used to determine if an exposure is potentially nontoxic or toxic. We encourage determination of toxicity and need for evaluation in consultation with a regional poison control center. (See <a class="local">'Indications for medical evaluation'</a> above and <a class="local">'Regional poison control centers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nontoxic exposures</strong> – Otherwise healthy patients with nontoxic ingestions of anticoagulant rodenticides such as exploratory ingestions in children do not require medical evaluation or laboratory testing. (See <a class="local">'Nontoxic exposures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxic exposures</strong> - These warrant timely evaluation for gastrointestinal decontamination and are subsequently managed based upon whether coagulopathy or bleeding are present. (See <a class="local">'Toxic exposures'</a> above.)</p><p></p><p class="bulletIndent1">Consultation with a hematologist and medical toxicologist is advised for any patient with bleeding after ingestion of an anticoagulant rodenticide. (See <a class="local">'Regional poison control centers'</a> above.)</p><p></p><p class="bulletIndent1">Patients with normal coagulation testing at 48 hours are <strong>not</strong> at risk of developing coagulopathy or bleeding. (See <a class="local">'No coagulopathy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gastrointestinal decontamination</strong> – In a patient who has ingested a toxic amount of anticoagulant rodenticide, we administer activated charcoal (AC) orally as long as the following conditions are met (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>) (see <a class="local">'Gastrointestinal decontamination'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Normal mental status and no aspiration risk</p><p class="bulletIndent3"><span class="glyph">-</span>Ingestion of an estimated dose that is &gt;1 mg of anticoagulant rodenticide</p><p class="bulletIndent3"><span class="glyph">-</span>AC can be administered within one hour of ingestion</p><p></p><p class="bulletIndent2">In a patient who presents more than one hour after ingestion, we individualize the decision to administer AC based upon the amount of rodenticide ingested, the potential for adverse effects of AC, and presence of other factors (eg, coingestants) that may slow gastric emptying.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with coagulopathy without bleeding</strong> – In the otherwise healthy patient with no bleeding after ingesting a superwarfarin, treatment should center on the measurement of prothrombin time (PT) and international normalized ratio (INR). These patients warrant modification of activities to avoid trauma. There is little agreement as to vitamin K<sub>1</sub> dosing and duration of therapy. (See <a class="local">'Coagulopathy but no bleeding'</a> above.)</p><p></p><p class="bulletIndent2">The evidence for this approach is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Treatment of supratherapeutic INR without bleeding'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>An INR of &lt;4.5 in a patient with no bleeding warrants only observation and serial monitoring.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In otherwise healthy patients with an INR ≥4.5 and no bleeding, we administer oral vitamin K<sub>1</sub> rather than intravenous vitamin K<sub>1</sub> to avoid the risk of anaphylaxis associated with intravenous administration. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a patient with an INR &gt;10 and who is <strong>not</strong> taking <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> regularly, we administer 2.5 to 5 mg vitamin K<sub>1</sub> orally with reassessment of the INR in 24 hours to determine need for an additional dose. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A patient who takes <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> regularly and ingests a warfarin-containing rodenticide should have their regimen managed and oral vitamin K<sub>1</sub> administered with input from their prescribing physician and according to the degree of INR elevation as discussed separately.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with coagulopathy and active bleeding</strong> – In a patient with life-threatening bleeding following anticoagulant rodenticide poisoning, we recommend administering a <a class="drug drug_general" data-topicid="9450" href="/z/d/drug information/9450.html" rel="external">4-factor prothrombin complex concentrate</a> (PCC), if available, or 3-factor PCC and <strong>either</strong> recombinant factor VIIa <strong>or</strong> fresh frozen plasma (FFP) (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). If neither 3-factor nor 4-factor PCC is available, then FFP should be given by rapid infusion  (<a class="graphic graphic_table graphicRef89478" href="/z/d/graphic/89478.html" rel="external">table 2</a>). Intravenous vitamin K<sub>1</sub> should also be given but does <strong>not</strong> have an immediate effect on restoring normal coagulation. Patients with major bleeding warrant hospitalization and bed rest until their coagulopathy is controlled. (See <a class="local">'Coagulopathy and active bleeding'</a> above.)</p><p></p><p class="bulletIndent2">Patients with minor bleeding should receive vitamin K<sub>1</sub> orally. Dosing is much higher and must continue for a longer duration after superwarfarin ingestion than when vitamin K<sub>1 </sub>is given for reversal of supratherapeutic INR due to <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>. If available, weekly measurement of quantitative superwarfarin concentrations can be helpful to guide duration of therapy.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Caravati EM, Erdman AR, Scharman EJ, et al. Long-acting anticoagulant rodenticide poisoning: An evidence-based consensus guideline for out-of-hospital management. Clinical Toxicol (Phila) 2007; 45:1.</li><li><a class="nounderline abstract_t">Watt BE, Proudfoot AT, Bradberry SM, Vale JA. Anticoagulant rodenticides. Toxicol Rev 2005; 24:259.</a></li><li><a class="nounderline abstract_t">Smolinske SC, Scherger DL, Kearns PS, et al. Superwarfarin poisoning in children: a prospective study. Pediatrics 1989; 84:490.</a></li><li><a class="nounderline abstract_t">Mullins ME, Brands CL, Daya MR. Unintentional pediatric superwarfarin exposures: do we really need a prothrombin time? Pediatrics 2000; 105:402.</a></li><li><a class="nounderline abstract_t">Shepherd G, Klein-Schwartz W, Anderson BD. Acute, unintentional pediatric brodifacoum ingestions. Pediatr Emerg Care 2002; 18:174.</a></li><li><a class="nounderline abstract_t">Ingels M, Lai C, Tai W, et al. A prospective study of acute, unintentional, pediatric superwarfarin ingestions managed without decontamination. Ann Emerg Med 2002; 40:73.</a></li><li><a class="nounderline abstract_t">Bruno GR, Howland MA, McMeeking A, Hoffman RS. Long-acting anticoagulant overdose: brodifacoum kinetics and optimal vitamin K dosing. Ann Emerg Med 2000; 36:262.</a></li><li><a class="nounderline abstract_t">Berny PJ, de Oliveira LA, Videmann B, Rossi S. Assessment of ruminal degradation, oral bioavailability, and toxic effects of anticoagulant rodenticides in sheep. Am J Vet Res 2006; 67:363.</a></li><li><a class="nounderline abstract_t">Hollinger BR, Pastoor TP. Case management and plasma half-life in a case of brodifacoum poisoning. Arch Intern Med 1993; 153:1925.</a></li><li><a class="nounderline abstract_t">Stanton T, Sowray P, McWaters D, Mount M. Prolonged anticoagulation with long-acting coumadin derivative: Case report of a brodifacoum poisoning with pharmacokinetic data. Blood 1988; 73:310a.</a></li><li><a class="nounderline abstract_t">Weitzel JN, Sadowski JA, Furie BC, et al. Surreptitious ingestion of a long-acting vitamin K antagonist/rodenticide, brodifacoum: clinical and metabolic studies of three cases. Blood 1990; 76:2555.</a></li><li><a class="nounderline abstract_t">Stanton T, Sowray P, McWaters D, Mount M. Prolonged anticoagulation with long-acting coumadin derivative: Case report of a brodifacoum poisoning with pharmacokinetic data. Blood 1988; 72:310a.</a></li><li><a class="nounderline abstract_t">Babcock J, Hartman K, Pedersen A, et al. Rodenticide-induced coagulopathy in a young child. A case of Munchausen syndrome by proxy. Am J Pediatr Hematol Oncol 1993; 15:126.</a></li><li><a class="nounderline abstract_t">Rubinstein I, Weinberg G, van Breemen R, et al. Treatment for long acting anticoagulant rodenticide poisoning - beyond INR monitoring? Toxicol Commun 2018; 2:59.</a></li><li><a class="nounderline abstract_t">Chong YK, Mak TW. Superwarfarin (Long-Acting Anticoagulant Rodenticides) Poisoning: from Pathophysiology to Laboratory-Guided Clinical Management. Clin Biochem Rev 2019; 40:175.</a></li><li><a class="nounderline abstract_t">Chu YJ, Lin JH, Hung DZ. Oral administration of injectable vitamin K1 in brodifacoum intoxication. Biomedicine (Taipei) 2022; 12:47.</a></li><li><a class="nounderline abstract_t">Routsolias JC, Gimbar RP, Zell-Kanter M. Clinical Pharmacists: Essential During a Poison Outbreak. J Med Toxicol 2020; 16:356.</a></li><li><a class="nounderline abstract_t">Yasaka M, Oomura M, Ikeno K, et al. Effect of prothrombin complex concentrate on INR and blood coagulation system in emergency patients treated with warfarin overdose. Ann Hematol 2003; 82:121.</a></li><li><a class="nounderline abstract_t">Zupancić-Salek S, Kovacević-Metelko J, Radman I. Successful reversal of anticoagulant effect of superwarfarin poisoning with recombinant activated factor VII. Blood Coagul Fibrinolysis 2005; 16:239.</a></li><li class="breakAll">Lai M, Ewald M. Anticoagulants. In: Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, Shannon MW, Borron SW, Burns MJ (Eds), Saunders, 2007. Vol 1051.</li><li><a class="nounderline abstract_t">Jähnchen E, Meinertz T, Gilfrich HJ, et al. Enhanced elimination of warfarin during treatment with cholestyramine. Br J Clin Pharmacol 1978; 5:437.</a></li><li><a class="nounderline abstract_t">Renowden S, Westmoreland D, White JP, Routledge PA. Oral cholestyramine increases elimination of warfarin after overdose. Br Med J (Clin Res Ed) 1985; 291:513.</a></li></ol></div><div id="topicVersionRevision">Topic 106877 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Caravati EM, Erdman AR, Scharman EJ, et al. Long-acting anticoagulant rodenticide poisoning: An evidence-based consensus guideline for out-of-hospital management. Clinical Toxicol (Phila) 2007; 45:1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16499407" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Anticoagulant rodenticides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2771552" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Superwarfarin poisoning in children: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10654963" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Unintentional pediatric superwarfarin exposures: do we really need a prothrombin time?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12066002" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Acute, unintentional pediatric brodifacoum ingestions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12085076" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A prospective study of acute, unintentional, pediatric superwarfarin ingestions managed without decontamination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10969235" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Long-acting anticoagulant overdose: brodifacoum kinetics and optimal vitamin K dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16454646" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Assessment of ruminal degradation, oral bioavailability, and toxic effects of anticoagulant rodenticides in sheep.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8250654" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Case management and plasma half-life in a case of brodifacoum poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prolonged anticoagulation with long-acting coumadin derivative: Case report of a brodifacoum poisoning with pharmacokinetic data</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2265249" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Surreptitious ingestion of a long-acting vitamin K antagonist/rodenticide, brodifacoum: clinical and metabolic studies of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prolonged anticoagulation with long-acting coumadin derivative: Case report of a brodifacoum poisoning with pharmacokinetic data</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8447555" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Rodenticide-induced coagulopathy in a young child. A case of Munchausen syndrome by proxy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30923779" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment for long acting anticoagulant rodenticide poisoning - beyond INR monitoring?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31857739" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Superwarfarin (Long-Acting Anticoagulant Rodenticides) Poisoning: from Pathophysiology to Laboratory-Guided Clinical Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35836972" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Oral administration of injectable vitamin K1 in brodifacoum intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32638283" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical Pharmacists: Essential During a Poison Outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12601493" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effect of prothrombin complex concentrate on INR and blood coagulation system in emergency patients treated with warfarin overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15870542" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Successful reversal of anticoagulant effect of superwarfarin poisoning with recombinant activated factor VII.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15870542" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Successful reversal of anticoagulant effect of superwarfarin poisoning with recombinant activated factor VII.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/656283" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Enhanced elimination of warfarin during treatment with cholestyramine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3928031" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Oral cholestyramine increases elimination of warfarin after overdose.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
